Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pediatric episodic migraine prevention study of fremanezumab versus placebo
NL-OMON56251Phase 3Recruiting
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Jul 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in migraine comparing Fremanezumab with Placebo (2 arms). Primary endpoint: Mean change from baseline in monthly average number of migraine days. Started Jul 2022; status: recruiting.
02
Drugs
fremanezumab
03
Conditions
migraine
Beyond the preview
Go deeper on NL-OMON56251.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON56251.